Survey - Lack of Confidence in Clinical Trial Data Delaying Drug Development
Clinical data challenges are hindering pharmaceutical companies' abilities to bring more drugs to the market faster. These challenges were addressed with a study commissioned by Oracle Health Sciences and conducted by Pharma Intelligence.
To begin, the survey revealed that 57 percent of the clinical researchers believe that their clinical data issues result in trial delays. In addition to trial delays, 81 percent of respondents cited data governance issues as the biggest challenge in meeting regulatory compliance which include duplicate data/inconsistent data, data quality, and data integrity/traceability.
When asked what the top three operational challenges were with their clinical trial data, 51 percent cited data completeness, 45 percent said data quality and 43 percent, data cleaning. Not surprisingly, over three-fourths of respondents cited inconsistent data and missing patient data as the most critical clinical data problems to catch in clinical trials.
To conclude, the top three risks highlighted by the research include the need for additional data reconciliation; incomplete data to determine efficacy and patient replacements.
Read the full release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
